Erythropoietin Peptide ARA290 Protects Brain Tissue After Ischemic Stroke in Mice

Cerebral ischemic stroke is a devastating neurological condition caused by interrupted blood flow to the brain, leading to neuronal death and long-term disability. Current treatments primarily focus on restoring blood flow, but there's a critical need for therapies that directly protect brain tissue from damage after the initial insult. This study investigates how the erythropoietin-derived peptide ARA290 mediates neuroprotection through the β-common receptor following ischemic stroke.

Treatment with ARA290 significantly reduced brain damage and improved functional outcomes in stroke mice. At 24 hours post-stroke, the ARA290 group exhibited a 35% reduction in infarct volume compared to the vehicle group (p<0.01), indicating substantial tissue preservation. Neurological deficit scores, assessing motor and sensory function, were also significantly lower in the ARA290 group, showing a 40% improvement by 7 days post-stroke (p<0.005). The study found that ARA290 treatment led to a 2.5-fold increase in anti-apoptotic protein Bcl-2 expression and a 1.8-fold decrease in pro-apoptotic Bax expression, alongside a 50% reduction in inflammatory markers like TNF-α and IL-6 in the ischemic penumbra. These protective effects were mediated through activation of the β-common receptor pathway, as evidenced by increased phosphorylation of STAT5 and Akt, key signaling molecules involved in cell survival.